




PHARMACEUTICAL 2021

Emergent BioSolutions Inc.
Rank 167 of 402

EMERGENT





PHARMACEUTICAL 2021

Emergent BioSolutions Inc.
Rank 167 of 402

EMERGENT

The relative strengths and weaknesses of Emergent BioSolutions Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Emergent BioSolutions Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 82% points. The greatest weakness of Emergent BioSolutions Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is 129%, being 82% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	1,195,900
Cost of Goods Sold	524,000
Intangible Assets	929,800
Liabilities, Current	384,500
Liabilities, Non-Current	964,300
Other Assets	113,400
Other Compr. Net Income	-15,400
Other Expenses	161,900
Other Liabilities	87,400
Other Net Income	-26,600
Other Revenues	1,555,400
Property and Equipment	644,100
Research and Development	234,500
Selling, General and Administrative Expense	303,300

Output Variable	Value in 1000 USD
Assets	2,883,200
Liabilities	1,436,200
Expenses	1,223,700
Revenues	1,555,400
Stockholders Equity	1,447,000
Net Income	305,100
Comprehensive Net Income	297,400
Economic Capital Ratio	129%